Summary of COVID-19 adintrevimab studies

1. Ison et al., Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

481 patient adintrevimab prophylaxis RCT: 75% fewer symptomatic cases (p=0.03).
PEP RCT 351 patients, showing lower COVID-19 cases with adintrevimab. The PrEP trial is listed separately [Ison].
Jun 2023, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofad314/7197273, https://c19p.org/isonpep

2. Ison et al., Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

2,002 patient adintrevimab prophylaxis RCT: 84% lower hospitalization (p=0.07) and 70% fewer symptomatic cases (p<0.0001).
PrEP RCT 1480 patients, showing lower COVID-19 cases with adintrevimab. The PEP trial is listed separately [Ison].
Jun 2023, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofad314/7197273, https://c19p.org/ison